Annovera

Drug Overview

Annovera represents a significant advancement in the Gynecology drug category. Designed to provide patient autonomy and long-acting reversible contraception (LARC), this medication belongs to the Drug Class of Vaginal Contraceptive Ring.

Operating as a sustained Hormone Modulator, this medication offers a distinct advantage over daily oral contraceptives by providing an entire year of pregnancy prevention through a single, reusable device.

• Generic Name: Segesterone acetate and ethinyl estradiol
• US Brand Names: Annovera
• Route of Administration: Vaginal insertion
• FDA Approval Status: Fully FDA-approved for the prevention of pregnancy in females of reproductive age.

What Is It and How Does It Work? (Mechanism of Action)

Annovera functions as a highly precise systemic Hormone Modulator by suppressing the hypothalamic-pituitary-ovarian (HPO) axis.

The ring is composed of a flexible silicone elastomer that continuously releases a daily dose of two hormones directly into the vaginal mucosa, which then enter the systemic bloodstream. These hormones are ethinyl estradiol (a synthetic estrogen) and segesterone acetate (a highly selective progestin). Segesterone acetate is unique because it specifically binds to progesterone receptors without binding to androgen or estrogen receptors, minimizing certain unwanted side effects like acne or hair growth.

When these hormones enter the blood, they signal the brain’s hypothalamus to stop producing Gonadotropin-Releasing Hormone (GnRH). Without GnRH, the pituitary gland stops secreting Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). Because FSH and LH are required to mature an ovarian follicle and trigger ovulation, their absence means the ovaries remain dormant and no egg is released.

Beyond central HPO axis suppression, this Targeted Therapy employs localized secondary mechanisms to prevent pregnancy. The progestin causes the cervical mucus to become thick and highly viscous, creating a physical barrier that prevents sperm from traveling into the uterus. Concurrently, the continuous hormonal exposure keeps the endometrial lining of the uterus thin and atrophic, creating an environment incapable of supporting the implantation of a fertilized egg.

FDA-Approved Clinical Indications

Primary Gynecological/Obstetric Indications

• Pregnancy Prevention: The primary, sole FDA-approved indication is the prevention of unintended pregnancy for up to one year (13 menstrual cycles).

Off-Label / Endocrinological Indications

• Menstrual Cycle Regulation: Used off-label to establish predictable withdrawal bleeding in patients with oligomenorrhea.
• Dysmenorrhea and Menorrhagia: Utilized to reduce the severity of pelvic cramping and decrease the volume of menstrual blood loss.
• Polycystic Ovary Syndrome (PCOS) Management: Prescribed to protect the uterine lining from hyperplasia and suppress excess ovarian hormone production.
• Endometriosis Symptom Management: Used to suppress natural ovarian estrogen production, limiting the painful cyclical flares of endometrial lesions.

Dosage and Administration Protocols

Annovera is unique because a single ring provides a full year (13 cycles) of contraception. It is inserted by the patient, left in place for 21 days, and removed for 7 days to allow for a withdrawal bleed.

Dose Adjustments and Special Populations:

Annovera is contraindicated in females with a Body Mass Index (BMI) greater than 29 kg/m2, as clinical data indicates reduced contraceptive efficacy in this population. The medication is also strictly contraindicated in patients with severe hepatic (liver) impairment, liver tumors, or acute viral hepatitis due to the liver’s role in metabolizing systemic hormones. No dose adjustments are indicated for mild renal (kidney) insufficiency.

Clinical Efficacy and Research Results

Clinical literature spanning 2020 to 2026 confirms the robust efficacy and secondary clinical benefits of the segesterone acetate and ethinyl estradiol vaginal ring. In pivotal clinical trials evaluating its primary use for pregnancy prevention, the Pearl Index (measuring the number of pregnancies per 100 women over one year) was approximately 2.98. This indicates highly effective pregnancy prevention when the ring is used as directed.

Current research also highlights significant improvements in secondary gynecological parameters. For patients suffering from primary dysmenorrhea, utilizing the Visual Analog Scale (VAS) for pelvic pain (scored 0 to 10), studies show an average reduction of 3 to 4 points over a six-month period of use. Additionally, patients experiencing heavy menstrual bleeding demonstrate a marked reduction in total menstrual blood volume, stabilizing hemoglobin levels and resolving secondary iron-deficiency anemia over the 13-cycle lifespan of the ring.

Safety Profile and Side Effects

BLACK BOX WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

Cigarette smoking exponentially increases the risk of serious cardiovascular events from combined hormonal contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Annovera is strictly contraindicated in women who are over 35 years old and smoke tobacco.

Common Side Effects (Occurring in more than 10 percent of patients)

• Headache or mild migraines.
• Nausea and mild gastrointestinal discomfort.
• Increased vaginal discharge or vaginal candidiasis (yeast infections).
• Breast tenderness or heightened sensitivity.
• Lower abdominal cramping or dysmenorrhea.

Serious Adverse Events and Management Strategies

• Venous Thromboembolism (VTE): The ethinyl estradiol component stimulates the hepatic synthesis of clotting factors. Patients face a statistically elevated risk of deep vein thrombosis (DVT), pulmonary embolism (PE), and ischemic stroke compared to non-users.
• Toxic Shock Syndrome (TSS): Though rare, TSS has been associated with the use of vaginal rings.
• Management: If a patient develops sudden severe headaches, chest pain, shortness of breath, or severe leg pain (ACHES warning signs), they must remove the ring and seek emergency medical intervention immediately. For TSS prevention, patients should seek immediate care if they develop a sudden high fever, vomiting, diarrhea, or a sunburn-like rash. Vaginal candidiasis can be managed with standard over-the-counter or prescription antifungal treatments without removing the ring.

Research Areas

While Annovera itself is an established contraceptive, the vaginal ring delivery mechanism represents a rapidly expanding frontier in gynecological Targeted Therapy. Current research (2023-2026) is heavily focused on using similar polymer rings as vectors for advanced medical interventions. Scientists are developing multi-purpose prevention technologies (MPTs) that utilize vaginal rings to simultaneously deliver contraception and antiretroviral medications to prevent HIV and other sexually transmitted infections. Furthermore, within regenerative medicine, researchers are exploring biodegradable vaginal rings designed to slowly elute localized tissue-healing agents, such as hyaluronic acid or localized low-dose estriol, to promote mucosal regeneration and stem cell proliferation in patients suffering from severe postmenopausal vaginal atrophy.

Disclaimer: Studies regarding multi-purpose prevention vaginal rings and biodegradable rings for mucosal regeneration are currently in the research phase and are not yet applicable to practical or professional clinical scenarios.

Patient Management and Practical Recommendations

Effective patient management ensures optimal contraceptive success, proper device hygiene, and adherence to cardiovascular safety protocols.

Pre-Treatment Tests

• Blood Pressure Screening: A baseline blood pressure reading is strictly required to rule out pre-existing hypertension before prescribing any estrogen-containing therapy.
• BMI Calculation: The physician must verify the patient’s BMI is under 30 kg/m2.
• Medical History: Comprehensive screening for a personal or familial history of thromboembolic disorders, severe migraines with aura, breast cancer, or active liver disease.

Precautions During Treatment

• Ring Expulsion: The ring may occasionally slip out during bowel movements, intercourse, or tampon removal. If expelled, it should be washed with mild soap and warm water and reinserted immediately. If left out for more than 2 hours, backup contraception is required for 7 days.
• STI Protection: Annovera offers zero protection against sexually transmitted infections. Barrier methods must be used with new or untested partners.
• Lubricants: Patients must avoid oil-based and silicone-based vaginal lubricants or treatments, as these can degrade the silicone elastomer of the ring and alter hormone release rates. Only water-based lubricants should be used.

Do’s and Don’ts

• DO wash the ring with mild, unscented soap and warm water before each insertion and after each removal.
• DO store the ring in its provided compact case at room temperature during the 7-day removal week. Keep it away from pets and extreme heat.
• DO use a calendar or smartphone reminder app to track exactly when to insert and remove the ring.
• DON’T throw the ring away after one month; it is designed to last for a full 13 cycles (1 year).
• DON’T smoke cigarettes or use e-cigarettes while using this medication, particularly if approaching age 35, to avoid severe cardiovascular complications.
• DON’T use the ring if you suspect you may be pregnant; remove it and take a pregnancy test immediately.

Legal Disclaimer

The medical information provided in this guide is intended solely for educational and informational purposes and does not constitute professional medical advice, diagnosis, or treatment. Always seek the direct advice of your physician, gynecologist, or other qualified healthcare provider regarding any questions you may have about family planning, contraception, or before starting, stopping, or altering any prescribed medication regimen.